Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.52 |
| ▸ | CNR1 | P21554 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20871893 | 1.00 | CNR2 (0.52) | CNR2CNR1CYP2C19ACHELMNA | |
| SCHEMBL20871882 | 0.94 | PYCR1 (0.47) | CNR2CNR1CYP2C19LMNAALDH1A1 | |
| SCHEMBL24455917 | 0.89 | CYP2C19 (0.61) | CNR2CNR1CYP2C19ACHELMNA | |
| SCHEMBL11776874 | 0.89 | CYP2C19 (0.61) | CNR2CNR1CYP2C19ACHELMNA | |
| SCHEMBL22340483 | 0.86 | CNR2 (0.53) | CNR2CNR1LMNAALDH1A1NPSR1 | |
| SCHEMBL29335488 | 0.86 | CNR2 (0.46) | CNR2CNR1LMNAALDH1A1NPSR1 | |
| SCHEMBL20871894 | 0.86 | CTSK (0.47) | CNR2CNR1LMNAALDH1A1NPSR1 | |
| SCHEMBL20871452 | 0.84 | CNR2 (0.65) | CNR2CNR1CYP2C19ACHELMNA | |
| SCHEMBL20870853 | 0.84 | CNR2 (0.65) | CNR2CNR1CYP2C19ACHELMNA | |
| SCHEMBL20871881 | 0.84 | BMP1 (0.45) | CNR2CNR1LMNAPYCR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034646-B2 | Method for the synthesis of unsymmetrical tertiary amines | Universite Paris-Saclay (FR) | 2021-06-15 | — | — | US | disclosed |
| US-20200255369-A1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | Universite Paris-Saclay (FR) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255369-A1 | NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES | ADH1C, ADH1A, ADH5 | CNR2 1633/4885CNR1 1297/4885CYP2C19 1740/4885 |
| US-11034646-B2 | Method for the synthesis of unsymmetrical tertiary amines | ADH1C, PNMT, ADH1A | CNR2 2182/4885CNR1 1767/4885CYP2C19 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.